These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 11641593

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group.
    Grotta J.
    Stroke; 1997 Dec; 28(12):2338-46. PubMed ID: 9412611
    [Abstract] [Full Text] [Related]

  • 4. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. European and Australian Lubeluzole Ischaemic Stroke Study Group.
    Diener HC.
    Cerebrovasc Dis; 1998 Dec; 8(3):172-81. PubMed ID: 9619701
    [Abstract] [Full Text] [Related]

  • 5. Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101,606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats.
    Yang Y, Li Q, Yang T, Hussain M, Shuaib A.
    J Neurosurg; 2003 Feb; 98(2):397-403. PubMed ID: 12593629
    [Abstract] [Full Text] [Related]

  • 6. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS).
    Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Höxter G, Mahagne MH.
    JAMA; 1995 Oct 04; 274(13):1017-25. PubMed ID: 7563451
    [Abstract] [Full Text] [Related]

  • 7. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke.
    Lang W, Stadler CH, Poljakovic Z, Fleet D, Lyse Study Group.
    Int J Stroke; 2013 Feb 04; 8(2):95-104. PubMed ID: 23009193
    [Abstract] [Full Text] [Related]

  • 8. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators.
    Clark WM, Albers GW, Madden KP, Hamilton S.
    Stroke; 2000 Apr 04; 31(4):811-6. PubMed ID: 10753980
    [Abstract] [Full Text] [Related]

  • 9. The rationale for new therapies in acute ischaemic stroke.
    Dyker AG, Lees KR.
    J Clin Pharm Ther; 1996 Dec 04; 21(6):377-91. PubMed ID: 9201564
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Lubeluzole in acute ischemic stroke. A double-blind, placebo-controlled phase II trial. Lubeluzole International Study Group.
    Diener HC, Hacke W, Hennerici M, Rådberg J, Hantson L, De Keyser J.
    Stroke; 1996 Jan 04; 27(1):76-81. PubMed ID: 8553408
    [Abstract] [Full Text] [Related]

  • 12. Combination therapy stroke trial. rt-PA +/- lubeluzole.
    Grotta J.
    Ann N Y Acad Sci; 2001 Jun 04; 939():309-10. PubMed ID: 11462784
    [No Abstract] [Full Text] [Related]

  • 13. Tissue plasminogen activator for acute ischemic stroke.
    National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
    N Engl J Med; 1995 Dec 14; 333(24):1581-7. PubMed ID: 7477192
    [Abstract] [Full Text] [Related]

  • 14. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke.
    Amaro S, Soy D, Obach V, Cervera A, Planas AM, Chamorro A.
    Stroke; 2007 Jul 14; 38(7):2173-5. PubMed ID: 17525395
    [Abstract] [Full Text] [Related]

  • 15. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.
    Stroke; 1997 Nov 14; 28(11):2109-18. PubMed ID: 9368550
    [Abstract] [Full Text] [Related]

  • 16. [Prospects of thrombolytic therapy for acute ischemic stroke].
    Nakashima T, Minematsu K.
    Brain Nerve; 2009 Sep 14; 61(9):1003-12. PubMed ID: 19803399
    [Abstract] [Full Text] [Related]

  • 17. Hyperacute stroke therapy with tissue plasminogen activator.
    Alberts MJ.
    Am J Cardiol; 1997 Aug 28; 80(4C):29D-34D; discussion 35D-39D. PubMed ID: 9284041
    [Abstract] [Full Text] [Related]

  • 18. Utilization of intravenous thrombolysis in 3-4.5 hours: analysis of the Minnesota stroke registry.
    Tekle WG, Chaudhry SA, Hassan AE, Peacock JM, Lakshminarayan K, Tsai A, Luepker R, Anderson DC, Qureshi AI.
    Cerebrovasc Dis; 2012 Aug 28; 34(5-6):400-5. PubMed ID: 23221276
    [Abstract] [Full Text] [Related]

  • 19. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.
    Patel SC, Levine SR, Tilley BC, Grotta JC, Lu M, Frankel M, Haley EC, Brott TG, Broderick JP, Horowitz S, Lyden PD, Lewandowski CA, Marler JR, Welch KM, National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
    JAMA; 2001 Dec 12; 286(22):2830-8. PubMed ID: 11735758
    [Abstract] [Full Text] [Related]

  • 20. Time of day, outcome, and response to thrombolytic therapy: the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trial experience.
    Rhoney DH, Coplin WM, Lin Y, Frankel M, Lyden PD, Levine SR.
    J Stroke Cerebrovasc Dis; 2010 Jan 12; 19(1):40-8. PubMed ID: 20123226
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.